Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 30, 2017

G1 Therapeutics to initiate Phase Ib/II trial for lung cancer

G1 Therapeutics has entered a clinical trial collaboration to assess its G1T38 in combination with AstraZeneca’s Tagrisso (osimertinib) in a Phase Ib/II clinical trial to treat patients suffering from EGFR mutation-positive non-small cell lung cancer (NSCLC).

G1 Therapeutics has entered a clinical trial collaboration to assess its G1T38 in combination with AstraZeneca’s Tagrisso (osimertinib) in a Phase Ib/II clinical trial to treat patients suffering from EGFR mutation-positive non-small cell lung cancer (NSCLC).

G1T38 is an investigational, oral CDK4/6 inhibitor designed to be used along with other targeted therapies for various oncology indications.

Tagrisso is an irreversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase developed to block EGFR-sensitising and EGFR T790M-resistance mutations.

The drug possesses clinical activity against central nervous system (CNS) metastases and its once-a-day 40mg and 80mg oral doses have been approved in more than 60 countries for EGFR T790M mutation-positive advanced NSCLC.

As per the agreement, G1 will conduct and fund the Phase Ib/II trial in alliance with AstraZeneca for subjects who have the EGFR T790M mutation and progressed on first-line EGFR inhibitors.

“CDK4/6 inhibitors can enhance the efficacy of targeted therapies, and G1T38 has already shown encouraging preclinical and initial clinical data that support a potential best-in-class profile.”

G1 Therapeutics CEO Mark Velleca said: “CDK4/6 inhibitors can enhance the efficacy of targeted therapies, and G1T38 has already shown encouraging preclinical and initial clinical data that support a potential best-in-class profile.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“The addition of G1T38 to Tagrisso in EGFR mutation-positive non-small cell lung cancer has the potential to prolong the time to disease progression by overcoming resistance mechanisms.”

Scheduled to be initiated in the first quarter of next year, the trial’s Phase Ib part will determine the recommended Phase II dose of G1T38 when combined with Tagrisso.

In the Phase II part, progression-free survival will be compared between the combination and Tagrisso monotherapy in a total of 108 patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU